172 related articles for article (PubMed ID: 36603185)
1. MYB insufficiency disrupts proteostasis in hematopoietic stem cells, leading to age-related neoplasia.
Clarke ML; Lemma RB; Walton DS; Volpe G; Noyvert B; Gabrielsen OS; Frampton J
Blood; 2023 Apr; 141(15):1858-1870. PubMed ID: 36603185
[TBL] [Abstract][Full Text] [Related]
2. MYB deficiency leads to myeloid neoplasia too.
Gonda TJ
Blood; 2023 Apr; 141(15):1786-1787. PubMed ID: 37052943
[No Abstract] [Full Text] [Related]
3. Determining c-Myb protein levels can isolate functional hematopoietic stem cell subtypes.
Sakamoto H; Takeda N; Arai F; Hosokawa K; Garcia P; Suda T; Frampton J; Ogawa M
Stem Cells; 2015 Feb; 33(2):479-90. PubMed ID: 25329760
[TBL] [Abstract][Full Text] [Related]
4. c-Myb associates with PML in nuclear bodies in hematopoietic cells.
Dahle Ø; Bakke O; Gabrielsen OS
Exp Cell Res; 2004 Jul; 297(1):118-26. PubMed ID: 15194430
[TBL] [Abstract][Full Text] [Related]
5. Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation.
Lieu YK; Reddy EP
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21689-94. PubMed ID: 19955420
[TBL] [Abstract][Full Text] [Related]
6. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.
Hess JL; Bittner CB; Zeisig DT; Bach C; Fuchs U; Borkhardt A; Frampton J; Slany RK
Blood; 2006 Jul; 108(1):297-304. PubMed ID: 16507773
[TBL] [Abstract][Full Text] [Related]
7. Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.
O'Rourke JP; Ness SA
Mol Cell Biol; 2008 Mar; 28(6):2091-101. PubMed ID: 18195038
[TBL] [Abstract][Full Text] [Related]
8. c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.
Liu W; Wu M; Huang Z; Lian J; Chen J; Wang T; Leung AY; Liao Y; Zhang Z; Liu Q; Yen K; Lin S; Zon LI; Wen Z; Zhang Y; Zhang W
Leukemia; 2017 Jan; 31(1):222-233. PubMed ID: 27457538
[TBL] [Abstract][Full Text] [Related]
9. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
Pattabiraman DR; Sun J; Dowhan DH; Ishii S; Gonda TJ
Mol Cancer Res; 2009 Sep; 7(9):1477-86. PubMed ID: 19737967
[TBL] [Abstract][Full Text] [Related]
10. Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.
Corradini F; Cesi V; Bartella V; Pani E; Bussolari R; Candini O; Calabretta B
J Biol Chem; 2005 Aug; 280(34):30254-62. PubMed ID: 15927960
[TBL] [Abstract][Full Text] [Related]
11. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
[TBL] [Abstract][Full Text] [Related]
12. In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis.
Vanhee S; De Mulder K; Van Caeneghem Y; Verstichel G; Van Roy N; Menten B; Velghe I; Philippé J; De Bleser D; Lambrecht BN; Taghon T; Leclercq G; Kerre T; Vandekerckhove B
Haematologica; 2015 Feb; 100(2):157-66. PubMed ID: 25381126
[TBL] [Abstract][Full Text] [Related]
13. A degradation-resistant c-Myb mutant cooperates with Bcl-2 in enhancing proliferative potential and survival of hematopoietic cells.
Corradini F; Bussolari R; Cerioli D; Lidonnici MR; Calabretta B
Blood Cells Mol Dis; 2007; 39(3):292-6. PubMed ID: 17644012
[TBL] [Abstract][Full Text] [Related]
14. Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis.
García P; Clarke M; Vegiopoulos A; Berlanga O; Camelo A; Lorvellec M; Frampton J
EMBO J; 2009 May; 28(10):1492-504. PubMed ID: 19360001
[TBL] [Abstract][Full Text] [Related]
15. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
[TBL] [Abstract][Full Text] [Related]
16. TALEN-mediated biallelic inactivation of MYB in human embryonic stem cell lines WAe001-A-45 and WAe001-A-46.
Fan C; Shah Z; Ullah H; Philonenko ES; Zhang B; Tan Y; Wang C; Zhang J; Samokhvalov IM
Stem Cell Res; 2020 Jul; 46():101854. PubMed ID: 32526676
[TBL] [Abstract][Full Text] [Related]
17. Identification and regulation of c-Myb target genes in MCF-7 cells.
Quintana AM; Liu F; O'Rourke JP; Ness SA
BMC Cancer; 2011 Jan; 11():30. PubMed ID: 21261996
[TBL] [Abstract][Full Text] [Related]
18. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia.
Zhao H; Jin S; Gewirtz AM
J Biol Chem; 2012 Jan; 287(2):925-34. PubMed ID: 22110127
[TBL] [Abstract][Full Text] [Related]
19. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells.
Zhao H; Kalota A; Jin S; Gewirtz AM
Blood; 2009 Jan; 113(3):505-16. PubMed ID: 18818396
[TBL] [Abstract][Full Text] [Related]
20. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
